ArriVent BioPharma, Inc.
AVBPNasdaq
$33.19
↑ +1.3%Jul 17 close · end-of-day
Price
1Y↑ +51.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.5B
Enterprise Value
$1.2B
P/E
—
P/S
—
P/B
4.6
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$145.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-44.8%
ROIC
—
Debt / Equity
—
Net Cash
$326.4M
Return 1Y
+46.1%
Company profile
We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. We were incorporated under the laws of the State of Delaware on April 14, 2021. Our principal executive offices are located at 18 Campus Boulevard, Suite 100, Newtown Square, PA.
- CEO
- Zhengbin (Bing) Yao
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Pennsylvania
- Website
- arrivent.com
Earnings
AVBP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.96↓ -49.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$74.6M | -$94.3M | -$177.5M |
| Net income | -$69.3M | -$80.5M | -$166.3M |
| Diluted EPS | -$32.38 | -$2.56 | -$4.32 |
| Operating cash flow | -$55.8M | -$70.2M | -$160.6M |
| Free cash flow | — | — | — |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$25.7M | -$24.2M | -$23.7M | -$66.8M | -$33.6M | -$38.3M | -$38.8M | -$46.1M |
| Net income | -$21.9M | -$20.6M | -$20.6M | -$64.4M | -$31.4M | -$35.0M | -$35.5M | -$43.3M |
| Diluted EPS | -$0.65 | -$0.61 | -$0.60 | -$1.90 | -$0.90 | -$0.83 | -$0.69 | -$0.96 |
| Operating cash flow | -$19.1M | -$16.3M | -$16.2M | -$68.0M | -$26.1M | -$35.8M | -$30.7M | -$41.9M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-10 | Hillhouse Capital Management, Ltd. | Sale | 555,555 | $23.37 | $13.0M | filing |
| 2025-07-11 | LaChapelle Robin· Chief Operating Officer | Option exercise | 6,503 | $2.28 | $14,826.84 | filing |
| 2025-07-11 | LaChapelle Robin· Chief Operating Officer | Option exercise | 2,600 | $2.28 | $5,928.00 | filing |
| 2025-07-11 | LaChapelle Robin· Chief Operating Officer | Option exercise | 2,050 | $2.28 | $4,674.00 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.